Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (ESR1 ...

Estrogen plays an important role in keeping bones healthy. Now, researchers investigated how membrane-initiated estrogen receptor alpha (mERα) signaling in specific cell types of female mice affects ...

•Oral selective estrogen receptor degraders are in multiple clinical trials with the potential to become a future mainstay of endocrine therapy. •Late relapse remains a key challenge of treating ...

Three-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Image by NIH Cancer cells proliferate despite a myriad of ...

Researchers at Case Western Reserve University School of Medicine have discovered how specific protein regions contribute to ...

Results from two clinical trials highlighted how new selective estrogen receptor degraders (SERDs) are showing promise in the treatment of breast cancer. Data from the phase II SERENA-2 trial offered ...

SAN ANTONIO – Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance), those who displayed a rising ESR1 mutation detected in their ...

Estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2) are the mainstay of breast cancer management, and their prevalence rates vary among ...

Vaginal estrogen therapy does not increase the risk for recurrence in women with hormone receptor (HR)–negative breast cancer or in those with HR–positive tumors concurrently treated with tamoxifen ...

Brussels, 6 May 2010 -- An international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed ...